Eslo-D

Quick links to important sections

Eslo-D

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eslo-D

Property Description
Active Ingredients Amlodipine, Hydrochlorothiazide
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Antihypertensive Agent
General Purpose Management of High Blood Pressure
Origin Synthetic

What Type of Medicine is Eslo-D and How is it Classified?

Eslo-D is a prescription-only, fixed-dose combination medicine, which means it contains two distinct active ingredients in a single oral tablet form. It is classified as an antihypertensive agent—a class of drugs used to manage high blood pressure (hypertension). The use of fixed-dose combination therapy is clinically recognized for potentially improving patient adherence compared to taking multiple pills. This dual-agent approach is typically indicated for adults whose hypertension remains uncontrolled when treated with just one medication.

Composition of Eslo-D: Which Active Ingredients Does it Contain?

The composition of Eslo-D is defined by its two principal ingredients, both of which are synthetically derived: Amlodipine and Hydrochlorothiazide (INN). Amlodipine is classified as a Calcium Channel Blocker (CCB), while Hydrochlorothiazide is a type of Thiazide diuretic. A key differentiating feature is that Eslo-D frequently incorporates the chirally pure S(-)Amlodipine component, which contributes the primary therapeutic benefit of the Amlodipine while potentially offering a favorable profile. The combination of these two pharmacological classes is widely utilized as an essential therapeutic strategy for reducing cardiovascular disease risk.

What is the General Purpose of Eslo-D?

The general purpose of Eslo-D is to achieve effective control over persistent hypertension that is not adequately managed by a single-drug treatment. The combined action of the two ingredients allows the medication to target blood pressure through two complementary methods: Amlodipine helps by relaxing and widening the blood vessels, while Hydrochlorothiazide aids the kidneys in the removal of excess salt and water from the body. This dual strategy is broadly adopted in clinical practice and delivers a combined blood pressure reduction that often surpasses the effect of either component administered alone. A typical use scenario involves initiating this combination after a patient has not reached target blood pressure goals on initial monotherapy.

Regulatory References

  1. NIH - Amlodipine & Hydrochlorothiazide Drug Information
  2. MedlinePlus Amlodipine Drug Information
  3. NICE Hypertension Guideline: Combination Therapy

What side effects are possible with Eslo-D?

Possible Side Effects and Safety Information

The official safety profile of this medicine, containing Amlodipine and Hydrochlorothiazide, is structured according to regulatory classifications of adverse reactions, ensuring neutral and medically grounded reporting. Safety data is organized by frequency and the body system affected, consistent with government regulatory documentation.

Frequency-Classified Adverse Reactions

Adverse reactions that are Common (ge 1/100 to <1/10) include peripheral edema (swelling), headache, dizziness, and fatigue. These effects, particularly headache and dizziness, are often reported at the start of treatment with the Amlodipine component. Reactions classified as Uncommon (ge 1/1,000 to <1/100) include hypotension, insomnia, and various skin rashes.

System-Organ-Class Groupings

The officially listed effects are grouped by the physiological system impacted, such as Vascular Disorders (e.g., flushing, edema) and Nervous System Disorders (e.g., somnolence, paresthesia). The Metabolism and Nutrition Disorders category covers consequences like electrolyte imbalances (e.g., hypokalemia) and hyperglycemia, primarily linked to the Hydrochlorothiazide component. Acute ocular disturbances, such as myopia and secondary angle-closure glaucoma, are documented under Eye Disorders.

Serious Adverse Reactions and Restrictions

Serious adverse reactions documented in regulatory sources include a risk of increased Angina Pectoris or Myocardial Infarction upon dosage initiation or increase. The medicine is contraindicated in specific patient groups due to safety restrictions, including individuals with anuria or severe renal impairment and those with severe hepatic impairment. Use during the second and third trimesters of pregnancy is also restricted due to the potential for fetal harm.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Eslo-D, a combination of Amlodipine and Hydrochlorothiazide, is officially documented to affect the cardiovascular and fluid/electrolyte balance systems, requiring immediate medical attention.

Documented Overdose Manifestations

Property Description
Cardiovascular Effects Manifests as profound and prolonged systemic hypotension due to excessive peripheral vasodilation (Amlodipine component), which can progress to shock. Signs may include bradycardia or reflex tachycardia.
Metabolic/Volume Effects Includes documented fluid and electrolyte imbalances such as hypokalemia, hyponatremia, and hypochloremic alkalosis from the diuretic component. Symptoms related to volume depletion, like lethargy and muscular fatigue, may occur.

Required Emergency Actions

The regulatory labels state that individuals must seek immediate medical attention for any suspected overdose. Hospital monitoring of cardiac and respiratory function is required due to the risk of life-threatening complications. Since no specific antidote is known for the Amlodipine component, treatment is restricted to symptomatic and supportive measures, including restoring volume with intravenous fluids and, if needed for resistant hypotension, the use of pressor agents. Patients with hepatic impairment require increased monitoring due to the risk of hepatic coma from the diuretic component.

Therapeutic Uses of Eslo-D

What Eslo-D Treats: Main Uses and Benefits

Eslo-D is a combination medication relevant for the management of Essential Hypertension (chronic high blood pressure) in adults. The primary therapeutic purpose is relevant for easing symptoms that interfere with daily comfort, as lowering blood pressure may assist with supporting the health of the heart, brain, and kidneys. This combination is applicable within clinical settings that involve acute or disruptive symptom patterns, often used during phases when blood pressure is persistently elevated. The medication's role is relevant for easing the impact of long-term risk factors, and it supports the stabilization of blood pressure, contributes to the easing of cardiovascular risk factors, and assists with managing volume manifestations. The use of one of the drug's components is commonly used to help with symptoms that interfere with daily comfort.


This medication provides supportive therapeutic benefit that can help lower the probability of severe cardiovascular complications. The combination is applied across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance and heightened physiological activity.


Quick Fact: Relief for Systemic Strain Eslo-D is applied in settings where short-term symptom stabilization is important, assisting with maintaining functional stability for patients whose hypertension involves both increased vascular tension and fluid retention.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Eslo-D — official regulatory information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults with hypertension not adequately controlled by monotherapy.

| Populations for whom use is contraindicated: | | | Anuria (absence of urine production) | Severe hepatic impairment or biliary cirrhosis/cholestasis | | Known hypersensitivity to Amlodipine, Hydrochlorothiazide, or any sulfonamide-derived drug | Severe hypotension or cardiogenic shock | | Refractory hypokalaemia, hyponatraemia, or hypercalcaemia | Second and third trimesters of pregnancy |

| Eligibility-related restrictions: | | | Age-Related: Use is not recommended for children and adolescents under 18 years, as safety and effectiveness are not established. Older adults may be more sensitive and require monitoring. | | Organ Function: Use is not recommended in patients with severe renal impairment (creatinine clearance le 30 mL/min). Use requires caution in patients with mild to moderate hepatic impairment. | | Pregnancy/Lactation: Contraindicated in the second and third trimesters of pregnancy. Use is not recommended during the first trimester or while breastfeeding. |


Eligibility Classifications (High-Level)

Official regulatory documents define who can and cannot use Eslo-D by establishing absolute prohibitions (Contraindications) and strong restrictions (Not Recommended). The eligibility profile permits use only in the specified adult population while formally excluding those with severe organ dysfunction, uncontrolled electrolyte imbalances, and pregnant or breastfeeding women. These classifications strictly determine the boundaries of authorized use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eslo-D, a fixed-dose combination, has documented interaction patterns strictly tied to its two active components, Amlodipine and Hydrochlorothiazide. Officially, co-administration with intravenous Dantrolene is contraindicated due to a risk of hyperkalemia. The combination with Lithium is generally not recommended, as the Hydrochlorothiazide component significantly reduces its renal clearance, thereby increasing the risk of lithium toxicity.

Pharmacokinetic constraints exist for the Amlodipine component. Strong or moderate CYP3A4 inhibitors (e.g., Clarithromycin, Diltiazem) may cause a significant increase in Amlodipine systemic exposure. A specific interaction mandates that the dose of Simvastatin must not exceed 20 mg daily when co-administered due to the resulting 77% increase in Simvastatin exposure. The risk of increased Amlodipine exposure caused by CYP3A4 inhibitors may also be more pronounced in elderly patients.

Pharmacodynamic interactions include the risk of a reduced antihypertensive effect when co-administered with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Substances like Alcohol, Barbiturates, or Narcotics may potentiate orthostatic hypotension. Furthermore, consumption of Grapefruit or Grapefruit Juice is not recommended as it may increase Amlodipine's bioavailability. The absorption of Hydrochlorothiazide is significantly reduced by anionic exchange resins, such as Cholestyramine and Colestipol.

Mechanism of Action

Modulating Vascular Tone through Calcium Channel Blockade

This core mechanism involves the action of Amlodipine, which specifically inhibits L-type Voltage-Dependent Calcium Channels on arteriolar smooth muscle cells. By preventing the influx of calcium ions ( Ca^2+), the drug directly promotes the relaxation and widening of peripheral arteries (vasodilation). This effect reduces the physical resistance against blood flow, initiating a change in the physiological forces exerted on the arterial walls.


Regulating Fluid Balance via Renal Cotransporter Inhibition

The second distinct mechanism is driven by Hydrochlorothiazide, which acts in the kidney's distal convoluted tubules by blocking the Sodium-Chloride Cotransporter (NCC). This inhibition reduces the reabsorption of salt and water back into the bloodstream, leading to increased urinary excretion (diuresis). The resulting decrease in circulatory fluid volume and associated long-term vascular changes provides a complementary pathway to affect the overall pressure profile.


Synergy of Independent Control Systems

The combination influences two independent physiological determinants: vascular resistance and circulatory volume. This dual mechanism results in a combined physiological effect that addresses two separate factors, resulting in a parallel modulation of resistance and volume.

Dosage and Administration Information

How to Use Eslo-D: Official Administration Guidelines

Eslo-D is a fixed-dose combination oral tablet (Amlodipine and Hydrochlorothiazide) intended for the long-term management of hypertension. Its administration must adhere strictly to established guidelines.


Standard Dosing and Administration

Instruction Official Rule
Route of Administration Oral use only.
Dosing Schedule One tablet once daily. The dose should be based on previously established component strengths.
Maximum Dose Should not exceed the maximum component limits of Amlodipine 10 mg and Hydrochlorothiazide 25 mg per day.
Food Relation May be taken with or without food.
Preparation The tablet must be swallowed whole with fluid and should not be crushed or chewed.
Timing The dose is taken once daily and is often recommended in the morning.

Use Protocol and Adjustments

Procedural Constraints

  • Therapy Initiation: Eslo-D is not indicated for initial therapy of hypertension; it is intended for use as replacement therapy or add-on/switch therapy.
  • Dose Titration: Dosage adjustments are allowed only after approximately two weeks of therapy, which allows the medication to achieve its full blood pressure lowering effect.
  • Pre-administration: Treatment should only commence after the correction of any pre-existing volume or salt depletion (e.g., low potassium or sodium levels).

Special Population Rules

  • Pediatric Use: Not recommended for use in patients under 18 years of age.
  • Severe Renal Impairment: Use is generally not recommended in patients with severe kidney impairment (creatinine clearance < 30 mL/min) due to the Hydrochlorothiazide component.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eslo-D


Evidence for Use in Essential Hypertension

The combination was studied for its role in adult patients with chronic high blood pressure, known as essential hypertension. The primary evidence base includes Randomized Controlled Trials (RCTs), which is the type of study used to assess the combination's role, alongside systematic reviews that compile data from multiple trials. These studies monitored outcomes such as the change in mean systolic and diastolic blood pressure (BP) readings and the frequency with which patients reached specific predetermined BP thresholds over defined time intervals.

Findings describe patterns observed in the studies where BP measurements data show patterns related to changes in blood pressure in the observed populations. The research highlights changes measured during the study period related to blood pressure metrics, which is consistent with the established effects of the two drug classes. However, these trials primarily focus on measuring BP itself, which is a measurable biological indicator.


Evidence for Patients Uncontrolled by Single-Drug Therapy

The combination medicine was studied for specific research contexts involving patients whose high blood pressure remained uncontrolled despite initial treatment with a single antihypertensive medication (monotherapy). These trials often involved RCTs designed to directly compare the fixed-dose combination against the single-drug treatment the patients were already receiving.

Studies report how symptoms evolved in the observed populations, generally describing patterns of changes measured during the study period which differed from those observed in the monotherapy comparator groups. Furthermore, the evidence contributes to understanding symptom patterns by suggesting that using a fixed-dose tablet may be associated with different patterns of patient adherence compared to a regimen requiring two separate pills.

It is still uncertain whether the findings apply equally to patients who failed different types of monotherapy drugs before starting the combination. Also, comparative evidence is lacking for how the findings for this specific combination compare to the results reported for other two-drug combination treatments for patients with uncontrolled hypertension.


What is Still Uncertain in the Research Landscape

There is limited information for long-term outcomes that specifically tracks patients taking the Eslo-D formulation for many years. The long-term effects on major health outcomes are largely derived from the body of evidence related to the component drug classes as a whole, which have been subject to long-term observation. The follow-up durations were limited in key studies, meaning the long-term effects are not fully established based on those specific studies. The evidence quality appears to vary across studies, and comparative evidence is often lacking for certain high-risk subgroups. Research provides context but does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Frequently Asked Questions (FAQ)

Common questions about Eslo-D (FAQ)


Q: How quickly does Eslo-D start working?

A: The diuretic component, Hydrochlorothiazide, begins its effect in the body relatively quickly, often within about one hour of administration. However, official information states that the maximum blood pressure lowering effect of the entire fixed-dose combination is typically reached after approximately two weeks of continuous daily use.


Q: Can Eslo-D cause weight gain?

A: The Amlodipine component may cause peripheral edema, which is swelling or fluid retention that patients might interpret as weight gain. Conversely, the Hydrochlorothiazide component is designed to help the body excrete excess salt and water, which often reduces fluid volume. Any concerns about unexpected weight changes should be brought to the attention of a healthcare provider.


Q: Why did my doctor prescribe Eslo-D if I'm already taking another pill?

A: Fixed-dose combination medicines like Eslo-D are often prescribed as a replacement or add-on strategy for adults whose high blood pressure remains uncontrolled on a single medication. This approach is recognized as addressing blood pressure through two independent mechanisms: vascular relaxation and fluid removal.


Q: Is it true that Eslo-D can affect your sleep?

A: Yes, official safety information documents that the components of this medicine may affect sleep patterns. Reported adverse reactions include both insomnia (difficulty falling or staying asleep) and somnolence (unusual or extreme sleepiness).


Q: What foods should I avoid while on Eslo-D?

A: Regulatory documents specifically advise against consuming Grapefruit or Grapefruit Juice. This is because these foods may affect how the Amlodipine component of the medicine is absorbed and processed by the body.


Q: Is Eslo-D used for fluid retention?

A: Yes, one of the active ingredients, Hydrochlorothiazide, is classified as a diuretic, sometimes called a 'water pill.' This component helps the kidneys increase the removal of excess salt and water from the body, which reduces circulatory fluid volume and can help manage swelling related to fluid buildup (edema).


Q: What do official sources say about stopping Eslo-D abruptly?

A: Official warnings related to the Amlodipine component state that worsening chest pain or heart attack can occur following a dosage change. Therefore, treatment changes, including stopping the medicine, are typically managed by a healthcare provider.


Q: Can Eslo-D make me feel tired or lethargic?

A: Yes, the official safety profile documents that feeling fatigued (tired) is a common adverse reaction, and somnolence (sleepiness) is also listed. These effects are usually most noticeable when a patient first begins taking the medicine.


Q: Does Eslo-D have a generic version available?

A: Both active ingredients in Eslo-D, Amlodipine and Hydrochlorothiazide, are widely available in generic form. The combination of these two components may also be available generically under various names, depending on the specific country or region.


Q: What is the difference between Eslo-D and other similar 'D' medicines?

A: Eslo-D is described as a fixed-dose combination containing two classes of antihypertensive agents: a Calcium Channel Blocker and a Thiazide Diuretic. Other combination medicines may contain different drug classes, such as Angiotensin Receptor Blockers (ARBs), which work through separate physiological pathways.


Q: What happens if I forget to take a dose of Eslo-D?

A: Patient instructions for similar combinations describe taking a dose as soon as the patient remembers if a dose is missed. However, if it is already close to the time of the next scheduled dose, the missed dose is typically skipped, and the patient takes the next dose at the regular time.


Q: Is it normal to feel dizzy when first starting Eslo-D?

A: Dizziness is listed in the official safety profile as a common side effect of the medicine. It is often reported by patients during the initial stages of treatment, consistent with the expected effects of the Amlodipine component.


Q: What should I do if I get a bad headache after taking Eslo-D?

A: Headache is listed as a common side effect, especially when beginning treatment. Patient information suggests resting, ensuring proper hydration, and consulting with a healthcare professional if the headache is severe or persistent. Headaches that are severe, persistent, or cause concern warrant consultation with a healthcare professional.


Q: How does Eslo-D compare to other dual-component medicines?

A: Clinical research, documented by regulatory bodies, has examined this specific combination against other two-drug treatments used for high blood pressure. These studies document the observed patterns of blood pressure reduction relative to the regimens used in the trials.


Q: Is there a risk of low potassium when taking Eslo-D?

A: Yes, the Hydrochlorothiazide component is classified as a diuretic, and the official safety profile documents the risk of developing low potassium (hypokalemia) levels. This is why medical monitoring, such as blood tests, may be performed during treatment.


Q: Can Eslo-D cause skin rashes or sensitivity to the sun?

A: The official safety information documents skin rashes as an uncommon side effect. Additionally, the Hydrochlorothiazide component is associated with photosensitivity, which is a condition where the skin is more sensitive to sunburn and other reactions when exposed to sunlight.


Q: How long has Eslo-D been available on the market?

A: Both active ingredients in Eslo-D—the Calcium Channel Blocker and the Thiazide Diuretic—belong to classes of medicines that have been approved and widely used in medical practice for the management of high blood pressure for many years.


Q: What are the general expectations for blood pressure control with Eslo-D?

A: The general purpose of the medicine is related to achieving control over persistent high blood pressure that is not managed by a single-drug treatment. Clinical studies monitored outcomes, including the achievement of specific predetermined blood pressure goals within observed patient populations.


Q: Can I drive a car while taking Eslo-D?

A: Patient safety guidelines suggest caution with activities requiring alertness, such as driving or operating machinery, until an individual knows how the medicine affects them. This warning is due to the possible side effects of dizziness or fatigue.

How should Eslo-D be stored and disposed of?

How to Store and Dispose of Eslo-D

Eslo-D tablets must be stored according to regulatory requirements to maintain the stability of the active ingredients. The medicine must be stored at room temperature, specifically below 30 C, and should be protected from direct sunlight and moisture. It is required to keep the tablets in their original packaging and ensure they are kept from freezing or excessive heat.

Child Safety and Disposal

It is mandatory to keep Eslo-D out of the sight and reach of children at all times. Unused or expired tablets should be disposed of using a community drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (such as dirt) and sealed in a container before disposal in the household trash. Do not dispose of the tablets by flushing them down the toilet or pouring them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eslo-D found in:

A-Z Index: